Technical Analysis for PRLD - Prelude Therapeutics Incorporated

Grade Last Price % Change Price Change
F 0.96 0.17% 0.00
PRLD closed up 0.17 percent on Wednesday, November 20, 2024, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.17%
Inside Day Range Contraction 0.17%
Wide Bands Range Expansion 0.17%
Oversold Stochastic Weakness 0.17%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
Up 3% about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prelude Therapeutics Incorporated Description

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor

Is PRLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.8
52 Week Low 0.931
Average Volume 385,203
200-Day Moving Average 3.80
50-Day Moving Average 1.80
20-Day Moving Average 1.22
10-Day Moving Average 1.08
Average True Range 0.12
RSI (14) 21.26
ADX 61.5
+DI 6.09
-DI 37.89
Chandelier Exit (Long, 3 ATRs) 1.43
Chandelier Exit (Short, 3 ATRs) 1.30
Upper Bollinger Bands 1.58
Lower Bollinger Band 0.85
Percent B (%b) 0.15
BandWidth 59.74
MACD Line -0.29
MACD Signal Line -0.31
MACD Histogram 0.0269
Fundamentals Value
Market Cap 40.37 Million
Num Shares 42 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 0.00
Price-to-Book 0.62
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.02
Resistance 3 (R3) 1.02 1.01 1.01
Resistance 2 (R2) 1.01 0.99 1.01 1.01
Resistance 1 (R1) 0.98 0.98 1.00 0.98 1.01
Pivot Point 0.97 0.97 0.97 0.97 0.97
Support 1 (S1) 0.94 0.95 0.96 0.94 0.92
Support 2 (S2) 0.93 0.94 0.93 0.92
Support 3 (S3) 0.90 0.93 0.91
Support 4 (S4) 0.90